JATT (NYSE:JATT) announced in an 8-K this morning that it will now issue 2,500,000 new shares to its FPA investors following the close of its business combination with Zura Bio.
FPA investors Athanor Master Fund and affiliates already agreed to expand their FPA purchases last month to 3,000,000 shares at $10 per share and provide a binding redemption backstop of $15 million covering any redemptions in excess of 90%.
With these backstop purchases, Athanor is to receive 1.087 shares for each Class A share that it bought that would have otherwise been redeemed above the threshold. As further compensation, JATT will now issue Athanor 2,500,000 new shares at close.
Should the backstop not be triggered, Athanor will receive its 5,500,00 shares in the combined company effectively at $5.45 per share. In the event the backstop is fully utilized, Athanor will be receiving a total of 7,130,500 shares at effectively $6.31 per share.
Overall, this new committed funding ensures that JATT, together with an existing $20 million PIPE, will meet the $65 million minimum cash condition of its business combination with Zura Bio. JATT shareholders are set to vote to complete the combination at a special meeting on March 16.
But, because only 2,500,000 of the 7,500,000 shares issued across the FPA and PIPE are to be done so below $10 per share (and $9.20 is the threshold), these moves are unlikely to trigger JATT’s Crescent Term. Under the terms of its prospectus, the exercise price of its warrants are only to be adjusted if newly issued securities below $9.20 represent more than 60%.
The parties initially announced their $215 million business combination in June 2022. London-based Zura Bio is a clinical-stage firm developing novel medicines for immune disorders with an initial focus on alopecia.
Terms Tracker for the Week Ending March 31, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Filings continue to remain quiet, but SPACs did manage to price two more IPOs this week with TMT Acquisition Corp (Nasdaq: TMTCU) and Trailblazer Merger...
Hudson Acquisition I Corp. (NASDAQ:HUDA) announced that it has signed a non-binding letter of intent (LOI) to combine with a pre-clinical-stage biotechnology company. The SPAC did not provide many details on the unnamed target, but disclosed that the biotech company is focused on developing intranasal preventives for major disease-causing respiratory viruses. As a condition to the target...
Heading into April, SPACs are to see eight sponsors and 11 de-SPAC’d companies freed from lock-ups and ready to trade. Most of these lock-up expirations are loaded into the final week of the month, but those hitting this milestone already next week include some of the more interesting transactions of the crop. In particular, MoonLake...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Shares of Digital World jump after Trump’s indictment, and pair of Delaware Chancery court decisions deny motions to dismiss SPAC shareholder’s fiduciary breach claims Trump-Tied SPAC’s Shares Jump After Historic New York Charge The...
Ares Acquisition Corporation II (NYSE:AACT) filed its S-1 yesterday afternoon for a $400 million IPO, marking the second SPAC to file for an IPO in March and the largest since December 20, 2021, when Gores Holdings X Inc. filed for a $725 million SPAC. Ares II intends to focus its search on an established target...